Hydralazine-d4 is intended for use as an internal standard for the quantification of hydralazine (Item No. 23121) by GC- or LC-MS. Hydralazine is an orally bioavailable vasodilator and antihypertensive agent.{40710} It decreases DNA methylation in Jurkat cells at a concentration of 10 ?M and inhibits extracellular and intracellular production of reactive oxygen species (ROS) in rat macrophages activated by phorbol 12-myristate 13-acetate (PMA; Item No. 10008014) at a concentration of 100 ?M.{40711,40712} Hydralazine (100 ?M) also decreases nitric oxide production and expression of inducible nitric oxide synthase (iNOS) in rat macrophages activated by LPS (Item Nos. 19660 | 19661 | 19662) and interferon-y (IFN-y).{40712} It reduces contraction of rat aortic arterial strips induced by potassium and norepinephrine (Item No. 16673; IC50s = 2.2 and 3.06 mM, respectively).{40713} Hydralazine (2.6 mg/kg) lowers mean arterial blood pressure (MAP) by 41.76% in conscious rats.{40714} Formulations containing hydralazine have been used in the treatment of high blood pressure and heart failure.
Specifications
Size
1 mg
Supplier
Cayman Chemical
Shipping & storage
Shipping condition
Dry Ice
Storage temperature
-20°C